Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,56999,recovery,A mean recovery of 102.6% (+/- 3.3% S.E.) was obtained using bleomycin added to normal sera.,Radioimmunoassay of bleomycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/56999/),%,102.6,9117,DB00290,Bleomycin
,73412,maximum concentrations,"Although all four agents have been reported to be clinically efficacious, in this tumor model, *I-fibrinogen and 67Ga-citrate had the greatest tumor accumulation with maximum concentrations of 11.7% and 10.5% respectively.","Comparison of oncophilic radiopharmaceuticals, *I-fibrinogen, 67Ga-citrate, 111In-bleomycin, and *I-bleomycin in tumor-bearing mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/73412/),%,11.7,12187,DB00290,Bleomycin
,73412,maximum concentrations,"Although all four agents have been reported to be clinically efficacious, in this tumor model, *I-fibrinogen and 67Ga-citrate had the greatest tumor accumulation with maximum concentrations of 11.7% and 10.5% respectively.","Comparison of oncophilic radiopharmaceuticals, *I-fibrinogen, 67Ga-citrate, 111In-bleomycin, and *I-bleomycin in tumor-bearing mice. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/73412/),%,10.5,12188,DB00290,Bleomycin
,2462650,concentrating,"The peplomycin concentrating in the serum after infusion for 24 hours thus were 0.094 microgram/ml and 0.056 microgram/ml, respectively.",[Pharmacokinetic and therapeutic studies of the administration of peplomycin by continuous subcutaneous infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462650/),[μg] / [ml],0.094,22210,DB00290,Bleomycin
,2462650,concentrating,"The peplomycin concentrating in the serum after infusion for 24 hours thus were 0.094 microgram/ml and 0.056 microgram/ml, respectively.",[Pharmacokinetic and therapeutic studies of the administration of peplomycin by continuous subcutaneous infusion]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462650/),[μg] / [ml],0.056,22211,DB00290,Bleomycin
,6206021,beta half-life (t1/2 beta),"In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t1/2 beta) of 1.3 hours, a terminal-phase half-life (t1/2) of 11.7 hours, a volume of distribution (Vd gamma) of 57.5L/m2, a total body clearance rate (C1b) of 52.8 ml/min/m2, a renal clearance rate (C1r) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose.",Pharmacokinetics of indium-111 BLEDTA in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206021/),h,1.3,23073,DB00290,Bleomycin
,6206021,terminal-phase half-life (t1/2),"In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t1/2 beta) of 1.3 hours, a terminal-phase half-life (t1/2) of 11.7 hours, a volume of distribution (Vd gamma) of 57.5L/m2, a total body clearance rate (C1b) of 52.8 ml/min/m2, a renal clearance rate (C1r) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose.",Pharmacokinetics of indium-111 BLEDTA in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206021/),h,11.7,23074,DB00290,Bleomycin
,6206021,volume of distribution (Vd gamma),"In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t1/2 beta) of 1.3 hours, a terminal-phase half-life (t1/2) of 11.7 hours, a volume of distribution (Vd gamma) of 57.5L/m2, a total body clearance rate (C1b) of 52.8 ml/min/m2, a renal clearance rate (C1r) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose.",Pharmacokinetics of indium-111 BLEDTA in man. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206021/),[l] / [m2],57.5,23075,DB00290,Bleomycin
,6206021,total body clearance rate (C1b),"In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t1/2 beta) of 1.3 hours, a terminal-phase half-life (t1/2) of 11.7 hours, a volume of distribution (Vd gamma) of 57.5L/m2, a total body clearance rate (C1b) of 52.8 ml/min/m2, a renal clearance rate (C1r) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose.",Pharmacokinetics of indium-111 BLEDTA in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206021/),[ml] / [m2·min],52.8,23076,DB00290,Bleomycin
,6206021,renal clearance rate (C1r),"In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t1/2 beta) of 1.3 hours, a terminal-phase half-life (t1/2) of 11.7 hours, a volume of distribution (Vd gamma) of 57.5L/m2, a total body clearance rate (C1b) of 52.8 ml/min/m2, a renal clearance rate (C1r) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose.",Pharmacokinetics of indium-111 BLEDTA in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206021/),[ml] / [m2·min],23.3,23077,DB00290,Bleomycin
,6206021,urinary excretion,"In eight patients studied by bolus intravenous injection, 111In-BLEDTA had a beta half-life (t1/2 beta) of 1.3 hours, a terminal-phase half-life (t1/2) of 11.7 hours, a volume of distribution (Vd gamma) of 57.5L/m2, a total body clearance rate (C1b) of 52.8 ml/min/m2, a renal clearance rate (C1r) of 23.3 ml/min/m2, and a 24-hour urinary excretion of 38.1% total administered dose.",Pharmacokinetics of indium-111 BLEDTA in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6206021/),%,38.1,23078,DB00290,Bleomycin
,17520830,in vivo recovery,The in vivo recovery of microdialysis probe was (42.8 +/- 3.4)% (n = 4).,[Pharmacokinetics of pingyangmycin hydrochloride in rabbits determined by microdialysis coupled with RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520830/),%,42.8,30678,DB00290,Bleomycin
,17520830,T1/2 alpha,"T1/2 alpha and T1/2 beta were 14.9 and 60.3 min, respectively.",[Pharmacokinetics of pingyangmycin hydrochloride in rabbits determined by microdialysis coupled with RP-HPLC]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520830/),min,14.9,30679,DB00290,Bleomycin
,17520830,T1/2 beta,"T1/2 alpha and T1/2 beta were 14.9 and 60.3 min, respectively.",[Pharmacokinetics of pingyangmycin hydrochloride in rabbits determined by microdialysis coupled with RP-HPLC]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17520830/),min,60.3,30680,DB00290,Bleomycin
,20649573,IC(50),"In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors.","A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649573/),nM,17,34167,DB00290,Bleomycin
,20649573,IC(50),"In vitro, AM966 inhibited LPA-stimulated intracellular calcium release (IC(50)= 17 nM) from Chinese hamster ovary cells stably expressing human LPA(1) receptors and inhibited LPA-induced chemotaxis (IC(50)= 181 nM) of human IMR-90 lung fibroblasts expressing LPA(1) receptors.","A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20649573/),nM,181,34168,DB00290,Bleomycin
,10447584,area under the plasma concentration-versus-time curves (AUC),"The mean paclitaxel area under the plasma concentration-versus-time curves (AUC) for the 125-mg/m(2) dose level (II) was 7.0 +/- 3.6 h micromol(-1) l(-1), for the 175-mg/m(2) dose level (III) 10.6 +/- 2.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[h] / [l·μmol],7.0,44420,DB00290,Bleomycin
,10447584,area under the plasma concentration-versus-time curves (AUC),"The mean paclitaxel area under the plasma concentration-versus-time curves (AUC) for the 125-mg/m(2) dose level (II) was 7.0 +/- 3.6 h micromol(-1) l(-1), for the 175-mg/m(2) dose level (III) 10.6 +/- 2.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),,10.6,44421,DB00290,Bleomycin
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],1.9,44422,DB00290,Bleomycin
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],3.4,44423,DB00290,Bleomycin
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[μM] / [l],4.3,44424,DB00290,Bleomycin
,10447584,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) values for dose levels II-V were 1.9 +/- 1.1 micromol/l, 3.4 +/- 1.2 micromol/l, 4.3 +/- 1.0 micromol/l and 3.8 +/- 1.2 h micromol/l, respectively.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),[h·μM] / [l],3.8,44425,DB00290,Bleomycin
>,10447584,t,"In this study, relevant pharmacokinetic parameters of paclitaxel like AUC, C(max) and the paclitaxel plasma concentration above the pharmacologically relevant 0.1-micromol/l threshold concentration (t > 0.1 microM) when administered in combination with cisplatin, etoposide and bleomycin (PEB) were not statistically different from paclitaxel data of historical controls.","Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10447584/),μM,0.1,44426,DB00290,Bleomycin
,30486979,IC50,"Furthermore, cell viability experiments using A549 lung adenocarcinoma cells revealed that the IC50 of PAA-cys-PAH-GO-PYM, free drug, and GO-PYM were 159.241 μM, 134.960 μM, and 129.815 μM respectively, indicating the higher retention and cytotoxicity of PYM in vitro.",Oral Delivery of Pingyangmycin by Layer-by-Layer (LbL) Self-Assembly Polyelectrolyte-Grafted Nano Graphene Oxide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30486979/),μM,159.241,52110,DB00290,Bleomycin
,30486979,IC50,"Furthermore, cell viability experiments using A549 lung adenocarcinoma cells revealed that the IC50 of PAA-cys-PAH-GO-PYM, free drug, and GO-PYM were 159.241 μM, 134.960 μM, and 129.815 μM respectively, indicating the higher retention and cytotoxicity of PYM in vitro.",Oral Delivery of Pingyangmycin by Layer-by-Layer (LbL) Self-Assembly Polyelectrolyte-Grafted Nano Graphene Oxide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30486979/),μM,134.960,52111,DB00290,Bleomycin
,30486979,IC50,"Furthermore, cell viability experiments using A549 lung adenocarcinoma cells revealed that the IC50 of PAA-cys-PAH-GO-PYM, free drug, and GO-PYM were 159.241 μM, 134.960 μM, and 129.815 μM respectively, indicating the higher retention and cytotoxicity of PYM in vitro.",Oral Delivery of Pingyangmycin by Layer-by-Layer (LbL) Self-Assembly Polyelectrolyte-Grafted Nano Graphene Oxide. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30486979/),μM,129.815,52112,DB00290,Bleomycin
,2469544,area under the plasma concentration vs time curve (AUC),"The carboplatin dose was calculated so as to achieve a constant area under the plasma concentration vs time curve (AUC) of 4.5 mg carboplatin/ml x min by using the formula: dose = 4.5 x (GFR + 25), where GFR is the absolute glomerular filtration rate measured by 51Cr-EDTA clearance.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[carboplatin·mg] / [min·ml],4.5,62522,DB00290,Bleomycin
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[mg] / [min·ml],4,62523,DB00290,Bleomycin
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,94,62524,DB00290,Bleomycin
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,129,62525,DB00290,Bleomycin
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],20.1,62526,DB00290,Bleomycin
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],155,62527,DB00290,Bleomycin
,2469544,AUC,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],102,62528,DB00290,Bleomycin
,2469544,beta-phase half-life (t 1/2 beta),"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],102,62529,DB00290,Bleomycin
,2469544,mean residence time (MRT,"The pharmacokinetics of carboplatin were the same on both the first and second courses, on which studies were carried out with overall mean +/- SD values (n = 8) of 4.8 +/- 0.6 mg/ml x min, 94 +/- 21 min, 129 +/- 21 min, 20.1 +/- 5.41, 155 +/- 33 ml/min and 102 +/- 24 ml/min for the AUC, beta-phase half-life (t 1/2 beta), mean residence time (MRT), volume of distribution (Vd) and total body (TCLR) and renal clearances (RCLR), respectively.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],102,62530,DB00290,Bleomycin
,2469544,renal clearance,The renal clearance of carboplatin was not significantly different from the GFR (132 +/- 32 ml/min).,Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],132,62531,DB00290,Bleomycin
,2469544,AUC,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[mg] / [min·ml],5.1,62532,DB00290,Bleomycin
,2469544,t 1/2 alpha,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,40,62533,DB00290,Bleomycin
,2469544,t 1/2 beta,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,257,62534,DB00290,Bleomycin
,2469544,MRT,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,292,62535,DB00290,Bleomycin
,2469544,Vd,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),,13.3,62536,DB00290,Bleomycin
,2469544,TCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],46,62537,DB00290,Bleomycin
,2469544,RCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],17.6,62538,DB00290,Bleomycin
,2469544,AUC,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[mg] / [min·ml],5.3,62539,DB00290,Bleomycin
,2469544,t 1/2 alpha,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,34,62540,DB00290,Bleomycin
,2469544,t 1/2 beta,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),min,242,62541,DB00290,Bleomycin
,2469544,Vd,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),,12.5,62542,DB00290,Bleomycin
,2469544,TCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],43,62543,DB00290,Bleomycin
,2469544,RCLR,"Etoposide pharmacokinetics were also the same on the two courses studied, with overall mean values +/- SD (n = 8) of: AUC = 5.1 +/- 0.9 mg/ml x min, t 1/2 alpha = 40 +/- 9 min, t 1/2 beta = 257 +/- 21 min, MRT = 292 +/- 25 min, Vd = 13.3 +/- 1.31, TCLR = 46 +/- 9 ml/min and RCLR = 17.6 +/- 6.3 ml/min when the drug was given alone and AUC = 5.3 +/- 0.6 mg/ml x min, t 1/2 alpha = 34 +/- 6 min, t 1/2 beta = 242 +/- 25 min, MRT = 292 +/- 25 min, Vd = 12.5 +/- 1.81, TCLR = 43 +/- 6 ml/min and RCLR = 13.4 +/- 3.5 ml/min when it was given in combination with carboplatin.",Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2469544/),[ml] / [min],13.4,62544,DB00290,Bleomycin
,27219676,Kd,"One of the representative compounds, 6j, binds to DDR1 with a Kd value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases.",Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27219676/),nM,4.7,87293,DB00290,Bleomycin
,27219676,IC50,"One of the representative compounds, 6j, binds to DDR1 with a Kd value of 4.7 nM and suppresses its kinase activity with an IC50 value of 9.4 nM, but it is significantly less potent for a panel of 400 nonmutated kinases.",Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27219676/),nM,9.4,87294,DB00290,Bleomycin
,9556164,maximum CSF concentration,The maximum CSF concentration of THP was 0.97% of plasma in patient A and 0.89% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),,0,95277,DB00290,Bleomycin
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,28.4,95278,DB00290,Bleomycin
,9556164,AUC,The CSF AUC of THP was 28.4% of plasma in patient A and 13.1% in patient B.,Pharmacokinetics of intra-arterially administered pirarubicin in plasma and cerebrospinal fluid of patients with glioma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9556164/),%,13.1,95279,DB00290,Bleomycin
,89025,peak serum level,"Bleomycin (1 mg/kg, ip) reached a peak serum level of 0.7-1.0 microgram/ml in 54 +/- 4 min (mean +/- SE) and was eliminated with a t 1/2 of 32 +/- 1 min.","Disposition of the pulmonary toxin, bleomycin. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),[μg] / [ml],0.7-1.0,98552,DB00290,Bleomycin
,89025,t 1/2,"Bleomycin (1 mg/kg, ip) reached a peak serum level of 0.7-1.0 microgram/ml in 54 +/- 4 min (mean +/- SE) and was eliminated with a t 1/2 of 32 +/- 1 min.","Disposition of the pulmonary toxin, bleomycin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),min,32,98553,DB00290,Bleomycin
,89025,apparent volume of distribution,The apparent volume of distribution in rats was 184 +/- 11 ml/kg.,"Disposition of the pulmonary toxin, bleomycin. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/89025/),[ml] / [kg],184,98554,DB00290,Bleomycin
,2410102,C X t,"Because a ""minimally toxic"" dose of bleomycin (approximately 0.1 mg/week) produces a CSF C X t of only 1.9 mg/min/ml, we believe that a Phase I clinical trial would be too dangerous given the limited therapeutic potential that a dose of 0.1 mg/week could achieve.",Central nervous system toxicity and cerebrospinal fluid pharmacokinetics of intraventricularly administered bleomycin in beagles. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410102/),[mg] / [min·ml],1.9,101475,DB00290,Bleomycin
,1718023,time to progression,For responding primary brain tumor patients the median time to progression was 33 weeks.,A pilot clinical and pharmacokinetic study of intracarotid cisplatin and bleomycin. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1718023/),weeks,33,108796,DB00290,Bleomycin
,6191713,half-life time (t1/2),"The half-life time (t1/2) of PEP-AC was estimated to be about 3 days by bioassay method, while about 60 min.",[Therapeutic effect of an antineoplastic agent (peplomycin) adsorbed on activated charcoal (PEP-AC)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6191713/),d,3,111691,DB00290,Bleomycin
,6191713,half-life time (t1/2),"The half-life time (t1/2) of PEP-AC was estimated to be about 3 days by bioassay method, while about 60 min.",[Therapeutic effect of an antineoplastic agent (peplomycin) adsorbed on activated charcoal (PEP-AC)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6191713/),min,60,111692,DB00290,Bleomycin
,7544945,t0.5,"ml-1, A5 released from the emulsion in a zero order rate with t0.5 of 12.0 h.",[Studies on gelatin microspheres-in-oil emulsion of pingyangmycin]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7544945/),h,12.0,116657,DB00290,Bleomycin
,15726371,area under the plasma concentration-time curve (AUC),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[h·μg] / [l],566,125229,DB00290,Bleomycin
,15726371,maximum plasma concentration (c(max)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[μg] / [l],599,125230,DB00290,Bleomycin
,15726371,elimination half-life (t(1/2)),"Non-compartmental analysis yielded an area under the plasma concentration-time curve (AUC) for Dx of 566 mug h L(-1), a maximum plasma concentration (c(max)) of 599 mug L(-1) and an elimination half-life (t(1/2)) of 30.8 h.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),h,30.8,125231,DB00290,Bleomycin
,15726371,clearance,"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],61.8,125232,DB00290,Bleomycin
,15726371,intercompartmental clearance (Q),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),[l] / [h],112,125233,DB00290,Bleomycin
,15726371,volume of the central compartment (V(1)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,23.3,125234,DB00290,Bleomycin
,15726371,volume of the peripheral compartment (V(2)),"Model estimate for Dx clearance was 61.8 L h(-1), for intercompartmental clearance (Q) 112 L h(-1), for the volume of the central compartment (V(1)) 23.3 L, and for the volume of the peripheral compartment (V(2)) 1,130 L.",Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726371/),l,"1,130",125235,DB00290,Bleomycin
,27475428,maximum tolerated dose,"Dose-limiting toxicities were reported in two of three patients at a TPCS2a dose of 1·5 mg/kg (skin photosensitivity [grade 3] and wound infection [grade 3]); thus, the maximum tolerated dose of TPCS2a was 1·0 mg/kg.","Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27475428/),mg,1,125753,DB00290,Bleomycin
,6155927,total plasma AUC (area under the plasma decay curve),The infusion minipump provided constant bleomycin plasma levels of 0.62 +/- 0.03 mu/ml and a total plasma AUC (area under the plasma decay curve) of 89.0 mu.h/ml for 6 days at 8 u/kg/day.,Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6155927/),[h·mu] / [ml],89.0,134799,DB00290,Bleomycin
,6155927,terminal-phase plasma t1/2,Intermittent bolus bleomycin at 8 u.kg/day had a terminal-phase plasma t1/2 of 15 min and a total 6-day plasma AUC of 90.8mu.h/ml.,Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6155927/),min,15,134800,DB00290,Bleomycin
,6155927,total 6-day,Intermittent bolus bleomycin at 8 u.kg/day had a terminal-phase plasma t1/2 of 15 min and a total 6-day plasma AUC of 90.8mu.h/ml.,Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6155927/),[h·mu] / [ml],90.8,134801,DB00290,Bleomycin
,6155927,plasma AUC,Intermittent bolus bleomycin at 8 u.kg/day had a terminal-phase plasma t1/2 of 15 min and a total 6-day plasma AUC of 90.8mu.h/ml.,Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6155927/),[h·mu] / [ml],90.8,134802,DB00290,Bleomycin
,6155927,peak bleomycin plasma levels,"Although high peak bleomycin plasma levels (i.e. 32 mu/ml) were achieved with the intermittent bolus administration, continuous-infusion bleomycin's greater inhibition of LCFU-S was probably related to the drug's schedule-dependent cell-killing characteristics.",Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6155927/),[mu] / [ml],32,134803,DB00290,Bleomycin
,6183016,initial half-life,"For patients who received IV bleomycin plasma disappearance was biphasic, with a mean initial half-life of 0.26 h and a terminal half-life of 2.3 h.",Bleomycin clinical pharmacology by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),h,0.26,137293,DB00290,Bleomycin
,6183016,terminal half-life,"For patients who received IV bleomycin plasma disappearance was biphasic, with a mean initial half-life of 0.26 h and a terminal half-life of 2.3 h.",Bleomycin clinical pharmacology by radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),h,2.3,137294,DB00290,Bleomycin
,6183016,plasma drug clearance,Mean plasma drug clearance was 67.8 ml/min/m2 and the volume of distribution was 13.2 l/m2.,Bleomycin clinical pharmacology by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),[ml] / [m2·min],67.8,137295,DB00290,Bleomycin
,6183016,volume of distribution,Mean plasma drug clearance was 67.8 ml/min/m2 and the volume of distribution was 13.2 l/m2.,Bleomycin clinical pharmacology by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),[l] / [m2],13.2,137296,DB00290,Bleomycin
,6183016,elimination half-life,"After SC administration peak plasma levels occurred in 1.1 h, with a mean elimination half-life of 4.3 h.",Bleomycin clinical pharmacology by radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),h,4.3,137297,DB00290,Bleomycin
,6183016,plasma drug clearance,Mean plasma drug clearance was 60.5 ml/min/m2 and the volume of distribution was 19.2 l/m2.,Bleomycin clinical pharmacology by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),[ml] / [m2·min],60.5,137298,DB00290,Bleomycin
,6183016,volume of distribution,Mean plasma drug clearance was 60.5 ml/min/m2 and the volume of distribution was 19.2 l/m2.,Bleomycin clinical pharmacology by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6183016/),[l] / [m2],19.2,137299,DB00290,Bleomycin
,24732397,bioavailability,"In addition, our nanoformulation, BLM-NLPs documented significantly (P<0.0001)∼3.4 fold (66.20±2.57%) higher bioavailability than BLM solution (19.56±0.79%).","Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24732397/),%,19.56,142778,DB00290,Bleomycin
,93509,elimination half-lives,The elimination half-lives of tallysomycin after iv and im administration were 1.51 +/- 0.41 hours and 2.40 +/- 0.667 hours respectively.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),h,1.51,143238,DB00290,Bleomycin
,93509,elimination half-lives,The elimination half-lives of tallysomycin after iv and im administration were 1.51 +/- 0.41 hours and 2.40 +/- 0.667 hours respectively.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),h,2.40,143239,DB00290,Bleomycin
,93509,elimination half-lives,These values were longer than the comparable iv (1.01 +/- 0.19 hours) and im (1.12 +/- 0.39 hours) elimination half-lives for bleomycin.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),h,1.12,143240,DB00290,Bleomycin
,93509,volume of distribution in the central compartment,The volume of distribution in the central compartment after iv administration was 0.111 +/- 0.039 liter/kg for tallysomycin and 0.125 +/- 0.0723 liter/kg for bleomycin.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),[l] / [kg],0.111,143241,DB00290,Bleomycin
,93509,volume of distribution in the central compartment,The volume of distribution in the central compartment after iv administration was 0.111 +/- 0.039 liter/kg for tallysomycin and 0.125 +/- 0.0723 liter/kg for bleomycin.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),[l] / [kg],0.125,143242,DB00290,Bleomycin
,93509,total apparent volumes of distribution,The total apparent volumes of distribution were 0.706 +/- 0.255 liter/kg and 0.388 +/- 0.245 liter/kg for tallysomycin and bleomycin respectively after iv injection.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),[l] / [kg],0.706,143243,DB00290,Bleomycin
,93509,total apparent volumes of distribution,The total apparent volumes of distribution were 0.706 +/- 0.255 liter/kg and 0.388 +/- 0.245 liter/kg for tallysomycin and bleomycin respectively after iv injection.,Pharmacokinetics of tallysomycin and bleomycin in the beagle dog. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/93509/),[l] / [kg],0.388,143244,DB00290,Bleomycin
,6166971,volume of distribution (Vdss),"The volume of distribution (Vdss) was 2.3 and 22.6 L/M2 for bleomycin and talisomycin, respectively.",Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166971/),[l] / [M2],2.3,143945,DB00290,Bleomycin
,6166971,volume of distribution (Vdss),"The volume of distribution (Vdss) was 2.3 and 22.6 L/M2 for bleomycin and talisomycin, respectively.",Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166971/),[l] / [M2],22.6,143946,DB00290,Bleomycin
,6166971,half-life (t1/2),The slower elimination of talisomycin was reflected by a half-life (t1/2) of 10.6 hr versus 1.6 hr for bleomycin.,Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166971/),h,10.6,143947,DB00290,Bleomycin
,6166971,half-life (t1/2),The slower elimination of talisomycin was reflected by a half-life (t1/2) of 10.6 hr versus 1.6 hr for bleomycin.,Preliminary studies of the pharmacokinetics of talisomycin in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6166971/),h,1.6,143948,DB00290,Bleomycin
,2445936,peak peritoneal: plasma concentration ratio,"The peak peritoneal: plasma concentration ratio averaged 22, and total exposure for the peritoneal cavity averaged seven-fold greater than that for the plasma.",The pharmacology of intraperitoneally administered bleomycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445936/),,22,151788,DB00290,Bleomycin
,2445936,peritoneal,"The peritoneal and plasma half-lives for bleomycin were 3.2 and 6.0 hours, respectively.",The pharmacology of intraperitoneally administered bleomycin. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445936/),h,3.2,151789,DB00290,Bleomycin
,2445936,plasma half-lives,"The peritoneal and plasma half-lives for bleomycin were 3.2 and 6.0 hours, respectively.",The pharmacology of intraperitoneally administered bleomycin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445936/),h,6.0,151790,DB00290,Bleomycin
,2445936,peritoneal clearance,The peritoneal clearance of bleomycin averaged 11.3 mL/min/m2.,The pharmacology of intraperitoneally administered bleomycin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2445936/),[ml] / [m2·min],11.3,151791,DB00290,Bleomycin
,63131,Tumor uptake,"Tumor uptake of the ICI preparation was constant from 2 to 24 hrs., and the tumor/blood ratio increased with time; with chloramine-T, this ratio decreased, and was less than that for ICI.",Comparison of I-bleomycin prepared by two methods stability and pharmacokinetics in tumor-bearing mice. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/63131/),h,2 to 24,156553,DB00290,Bleomycin
,1384141,half-life,"In patients with renal compromise or extensive prior cisplatin therapy, the drug half-life can extend from 2 to 4 hours up to 21 hours.","Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1384141/),h,2 to 4,156643,DB00290,Bleomycin
,1384141,half-life,"In patients with renal compromise or extensive prior cisplatin therapy, the drug half-life can extend from 2 to 4 hours up to 21 hours.","Bleomycin pharmacology: mechanism of action and resistance, and clinical pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1384141/),h,21,156644,DB00290,Bleomycin
,2412684,peritoneal fluid half-life,Pharmacokinetics of serum and intraperitoneal bleomycin showed peak levels at 15 minutes with a peritoneal fluid half-life of 4.2 +/- 0.1 hours and a serum half-life of 5.0 +/- 1.2 hours.,Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2412684/),h,4.2,171053,DB00290,Bleomycin
,2412684,serum half-life,Pharmacokinetics of serum and intraperitoneal bleomycin showed peak levels at 15 minutes with a peritoneal fluid half-life of 4.2 +/- 0.1 hours and a serum half-life of 5.0 +/- 1.2 hours.,Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2412684/),h,5.0,171054,DB00290,Bleomycin
,6188571,t1/2 alpha,"After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t1/2 alpha and t1/2 beta of 0.3 +/- 0.1 and 3.2 +/- 0.7 hr (mean +/- SEM).",Bleomycin disposition in children with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),h,0.3,171439,DB00290,Bleomycin
,6188571,t1/2 beta,"After intravenous bolus, bleomycin concentrations were adequately described by a two-compartment open model with a mean t1/2 alpha and t1/2 beta of 0.3 +/- 0.1 and 3.2 +/- 0.7 hr (mean +/- SEM).",Bleomycin disposition in children with cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),h,3.2,171440,DB00290,Bleomycin
,6188571,Volume of the central compartment,Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 +/- 0.5 and 9.9 +/- 1.1 l/m2.,Bleomycin disposition in children with cancer. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[l] / [m2],4.3,171441,DB00290,Bleomycin
,6188571,volume of distribution at steady-state (Vss),Volume of the central compartment and volume of distribution at steady-state (Vss) were 4.3 +/- 0.5 and 9.9 +/- 1.1 l/m2.,Bleomycin disposition in children with cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[l] / [m2],9.9,171442,DB00290,Bleomycin
,6188571,Total plasma (CLT),Total plasma (CLT) and renal (CLR) clearance were 51.8 +/- 6.1 and 33.5 +/- 2.4 ml/min/m2.,Bleomycin disposition in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],51.8,171443,DB00290,Bleomycin
,6188571,renal (CLR) clearance,Total plasma (CLT) and renal (CLR) clearance were 51.8 +/- 6.1 and 33.5 +/- 2.4 ml/min/m2.,Bleomycin disposition in children with cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],33.5,171444,DB00290,Bleomycin
,6188571,CLT,Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (greater than 300 mg/m2); CLT and CLR for these courses were 18.0 +/- 3.3 and 8.2 ml/min/m2.,Bleomycin disposition in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],18.0,171445,DB00290,Bleomycin
,6188571,CLR,Three intravenous bolus courses were given to two patients who received more than four courses of cisplatin (greater than 300 mg/m2); CLT and CLR for these courses were 18.0 +/- 3.3 and 8.2 ml/min/m2.,Bleomycin disposition in children with cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],8.2,171446,DB00290,Bleomycin
,6188571,plasma t1/2,"Mean values for plasma t1/2, Vss, CLT, and CLR were 2.1 +/- 0.1 hr, 11.0 +/- 2.6 l/m2, 57.1 +/- 13.5 ml/min/m2, and 33.2 +/- 6.4 ml/min/m2.",Bleomycin disposition in children with cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),h,2.1,171447,DB00290,Bleomycin
,6188571,Vss,"Mean values for plasma t1/2, Vss, CLT, and CLR were 2.1 +/- 0.1 hr, 11.0 +/- 2.6 l/m2, 57.1 +/- 13.5 ml/min/m2, and 33.2 +/- 6.4 ml/min/m2.",Bleomycin disposition in children with cancer. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[l] / [m2],11.0,171448,DB00290,Bleomycin
,6188571,CLT,"Mean values for plasma t1/2, Vss, CLT, and CLR were 2.1 +/- 0.1 hr, 11.0 +/- 2.6 l/m2, 57.1 +/- 13.5 ml/min/m2, and 33.2 +/- 6.4 ml/min/m2.",Bleomycin disposition in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[l] / [m2],11.0,171449,DB00290,Bleomycin
,6188571,CLR,"Mean values for plasma t1/2, Vss, CLT, and CLR were 2.1 +/- 0.1 hr, 11.0 +/- 2.6 l/m2, 57.1 +/- 13.5 ml/min/m2, and 33.2 +/- 6.4 ml/min/m2.",Bleomycin disposition in children with cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],33.2,171450,DB00290,Bleomycin
,6188571,CLT,One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2.,Bleomycin disposition in children with cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],4.8,171451,DB00290,Bleomycin
,6188571,CLR,One patient received his bleomycin infusion when ureteral obstruction was present; CLT and CLR for this course were 4.8 and 4.1 ml/min/m2.,Bleomycin disposition in children with cancer. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6188571/),[ml] / [m2·min],4.1,171452,DB00290,Bleomycin
,2849466,clearance,A daily dose of 60 mg/m2 of cisplatin in a person with a body surface of 1.7 m2 and EDTA clearance of 100 ml/min was equivalent to 0.69 mg cisplatin/l EDTA clearance/24 h.,EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),[ml] / [min],100,175510,DB00290,Bleomycin
,2849466,clearance,A daily dose of 60 mg/m2 of cisplatin in a person with a body surface of 1.7 m2 and EDTA clearance of 100 ml/min was equivalent to 0.69 mg cisplatin/l EDTA clearance/24 h.,EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),c·mg,0.69,175511,DB00290,Bleomycin
,2849466,clearance,The mean daily cisplatin dose (mean) in the whole group was 0.86 mg/l EDTA clearance/24 h (range 0.35-2.00).,EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),[mg] / [l],0.86,175512,DB00290,Bleomycin
,2849466,clearance,Patients with PD received a significantly lower cisplatin dose than the whole group (0.61 versus 0.86 mg cisplatin/l EDTA clearance/24 h x 4.),EDTA clearance in monitoring cisplatin dose escalation in patients with bulky metastatic germ cell tumors of the testis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2849466/),,0.86,175513,DB00290,Bleomycin
,78932,time to reach steady state,The time to reach steady state following the long infusion (ca. 12 hours) was consistent with the half-life (3 hours) predicted by the short infusion and the long infusion excluding levels less than 10 microunits/ml.,The pharmacokinetics of bleomycin in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/78932/),h,12,189741,DB00290,Bleomycin
,78932,half-life,The time to reach steady state following the long infusion (ca. 12 hours) was consistent with the half-life (3 hours) predicted by the short infusion and the long infusion excluding levels less than 10 microunits/ml.,The pharmacokinetics of bleomycin in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/78932/),h,3,189742,DB00290,Bleomycin
,6165473,peak serum concentrations,"Mean peak serum concentrations of 0.133, 0.326, and 0.587 milliunits/ml were obtained approximately 1 hour after injection of 2, 5, and 10 units/m2, respectively.",Pharmacokinetics of bleomycin after im administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165473/),[milliunits] / [ml],0.133,199245,DB00290,Bleomycin
,6165473,peak serum concentrations,"Mean peak serum concentrations of 0.133, 0.326, and 0.587 milliunits/ml were obtained approximately 1 hour after injection of 2, 5, and 10 units/m2, respectively.",Pharmacokinetics of bleomycin after im administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165473/),[milliunits] / [ml],0.326,199246,DB00290,Bleomycin
,6165473,peak serum concentrations,"Mean peak serum concentrations of 0.133, 0.326, and 0.587 milliunits/ml were obtained approximately 1 hour after injection of 2, 5, and 10 units/m2, respectively.",Pharmacokinetics of bleomycin after im administration in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165473/),[milliunits] / [ml],0.587,199247,DB00290,Bleomycin
,6165473,half-life,"The mean half-life was 155 minutes, with a range of 65--235 minutes.",Pharmacokinetics of bleomycin after im administration in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165473/),min,155,199248,DB00290,Bleomycin
,6165473,urinary excretion,"The urinary excretion of bleomycin was 61% during the 24 hours after injection, with some variability that was not explained by differences in dose or creatinine clearance.",Pharmacokinetics of bleomycin after im administration in man. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6165473/),%,61,199249,DB00290,Bleomycin
,2462625,half-life,BLM showed first order plasma elimination kinetics over 30 min in both strains with a shorter half-life in the sensitive strain (9.6 +/- 0.3 min in C57Bl/6N vs. 12.7 +/- 1.9 min in BALB/c).,Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462625/),min,9.6,199908,DB00290,Bleomycin
,2462625,half-life,BLM showed first order plasma elimination kinetics over 30 min in both strains with a shorter half-life in the sensitive strain (9.6 +/- 0.3 min in C57Bl/6N vs. 12.7 +/- 1.9 min in BALB/c).,Plasma and pulmonary pharmacokinetics of bleomycin in murine strains that are sensitive and resistant to bleomycin-induced pulmonary fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2462625/),min,12.7,199909,DB00290,Bleomycin
,12615626,Kep,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),1/[minutes],2.5 x 10(-3),200231,DB00290,Bleomycin
,12615626,Kep,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),1/[minutes],1.7 x 10(-3),200232,DB00290,Bleomycin
,12615626,T1/2,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),min,121.6,200233,DB00290,Bleomycin
,12615626,T1/2,"On Day 7 with multifocal intraalveolar exudative changes, Kep in affected areas was significantly increased compared with baseline (2.5 x 10(-3) minutes(-1) +/- 0.3 versus 1.7 x 10(-3) minutes(-1) +/- 0.2, p < 0.0001), with significant decrease in T1/2 (121.6 +/- 19.7 minutes vs. 170.4 +/- 15.8 minutes, p < 0.001).",Altered clearance of gadolinium diethylenetriaminepentaacetic acid aerosol from bleomycin-injured dog lungs: initial observations. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12615626/),min,170.4,200234,DB00290,Bleomycin
,9972368,mean transit time,"The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),min,14,203271,DB00290,Bleomycin
,9972368,mean transit time,"The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),h,1.8,203272,DB00290,Bleomycin
,9972368,mean transit time,"The mean transit time of 111In-BLMC in the plasma pool was 14 +/- 7 min without and 1.8 +/- 0.6 h when accounting for recirculation, and 13 +/- 4 h in the total body pool.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),h,13,203273,DB00290,Bleomycin
,9972368,plasma clearance,The mean plasma clearance of 111In-BLMC was 0.3 +/- 0.1 m/blood/min and the mean half-life in urine was 3.5 +/- 0.6 h.,Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),[m] / [blood·min],0.3,203274,DB00290,Bleomycin
,9972368,half-life in urine,The mean plasma clearance of 111In-BLMC was 0.3 +/- 0.1 m/blood/min and the mean half-life in urine was 3.5 +/- 0.6 h.,Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),h,3.5,203275,DB00290,Bleomycin
,9972368,transfer coefficients,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,0.02,203276,DB00290,Bleomycin
,9972368,transfer coefficients,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),10,12,203277,DB00290,Bleomycin
,9972368,transfer coefficients,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,0.01,203278,DB00290,Bleomycin
,9972368,transfer coefficients,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,0.39,203279,DB00290,Bleomycin
,9972368,transfer coefficients,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,1.11,203280,DB00290,Bleomycin
,9972368,excretion,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,0.02,203281,DB00290,Bleomycin
,9972368,excretion,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),10,12,203282,DB00290,Bleomycin
,9972368,excretion,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,0.01,203283,DB00290,Bleomycin
,9972368,excretion,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,0.39,203284,DB00290,Bleomycin
,9972368,excretion,"The mean transfer coefficients for the open three-compartmental model were: excretion from plasma = 0.02 +/- 0.01, from depot to plasma = (12 +/- 9)*10(-4), from plasma to depot = 0.01 +/- 0.01, from tumor to plasma = 0.39 +/- 0.19 and from plasma to tumor = 1.11 +/- 0.57, all in units minute-1.",Kinetics of 111In-labeled bleomycin in patients with brain tumors: compartmental vs. non-compartmental models. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9972368/),,1.11,203285,DB00290,Bleomycin
,6160601,terminal-phase plasma half-life,"Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose.","The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,5.5,212050,DB00290,Bleomycin
,6160601,terminal-phase plasma half-life,"Although IP bleomycin had a somewhat longer terminal-phase plasma half-life than after intravenous (IV) administration (5.5 vs 4.0 h, respectively), its systemic absorption averaged only 44%-52% of the administered dose.","The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,4.0,212051,DB00290,Bleomycin
,6160601,terminal-phase half-life,IP melphalan's mean terminal-phase half-life of 1.3 h was similar to that seen after IV drug administration.,"The disposition of intraperitoneal bleomycin, melphalan, and vinblastine in cancer patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6160601/),h,1.3,212052,DB00290,Bleomycin
,20109123,alveolar half-life,"The local alveolar anticoagulant effect was detectable up to 72 h, and the alveolar half-life was estimated at 28 h.",Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20109123/),h,28,216707,DB00290,Bleomycin
,73408,steady state plasma level,Patients receiving 30 units per day attained an average steady state plasma level of 145.8 (+/- 43.1) ng/ml bleomycin.,Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/73408/),[ng] / [ml],145.8,217334,DB00290,Bleomycin
,73408,t 1/2,Elimination of bleomycin was initially described by first order rate kinetics (t 1/2 = 1.32 +/- 0.39 hour).,Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/73408/),h,1.32,217335,DB00290,Bleomycin
,73408,t 1/2,"However, at times greater than 12 hours following termination of infusion, a second elimination phase was observed (t 1/2 = 8.9 +/- 2.7 hour).",Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/73408/),h,8.9,217336,DB00290,Bleomycin
,73408,steady state bleomycin concentration,This patient attained a steady state bleomycin concentration of 1046 ng/ml and exhibited a terminal elimination half-life of 33 hours.,Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/73408/),[ng] / [ml],1046,217337,DB00290,Bleomycin
,73408,terminal elimination half-life,This patient attained a steady state bleomycin concentration of 1046 ng/ml and exhibited a terminal elimination half-life of 33 hours.,Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/73408/),h,33,217338,DB00290,Bleomycin
,17360133,entrapment efficiency (EE%),The MSs showed a rather high entrapment efficiency (EE%) of 87.6+/-5.7% and the drug loading efficacy (DL%) was 20.2+/-1.3%.,Preparation and characterization of Pingyangmycin-loaded bovine serum albumin microspheres for embolization therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17360133/),%,87.6,223806,DB00290,Bleomycin
,17360133,drug loading efficacy (DL%),The MSs showed a rather high entrapment efficiency (EE%) of 87.6+/-5.7% and the drug loading efficacy (DL%) was 20.2+/-1.3%.,Preparation and characterization of Pingyangmycin-loaded bovine serum albumin microspheres for embolization therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17360133/),%,20.2,223807,DB00290,Bleomycin
,21159750,IC₅₀,"In vitro, AM095 was a potent LPA₁ receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA₁ with IC₅₀ values of 0.98 and 0.73 μM, respectively, and exhibited no LPA₁ agonism.",Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159750/),μM,0.98,236016,DB00290,Bleomycin
,21159750,IC₅₀,"In vitro, AM095 was a potent LPA₁ receptor antagonist because it inhibited GTPγS binding to Chinese hamster ovary (CHO) cell membranes overexpressing recombinant human or mouse LPA₁ with IC₅₀ values of 0.98 and 0.73 μM, respectively, and exhibited no LPA₁ agonism.",Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159750/),μM,0.73,236017,DB00290,Bleomycin
,21159750,IC₅₀,"In functional assays, AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA₁ (IC₅₀= 778 nM) and human A2058 melanoma cells (IC₅₀ = 233 nM).",Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159750/),nM,778,236018,DB00290,Bleomycin
,21159750,IC₅₀,"In functional assays, AM095 inhibited LPA-driven chemotaxis of CHO cells overexpressing mouse LPA₁ (IC₅₀= 778 nM) and human A2058 melanoma cells (IC₅₀ = 233 nM).",Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21159750/),nM,233,236019,DB00290,Bleomycin
,7680282,ne,"At the maximally tolerated IdUrd dose of 2780 mg/m2/day, the median neutrophil nadir after the first cycle of therapy was 805/microliters and the median platelet nadir was 48,000/microliters.",Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7680282/),1/[μl],805,236272,DB00290,Bleomycin
,7680282,platelet nadir,"At the maximally tolerated IdUrd dose of 2780 mg/m2/day, the median neutrophil nadir after the first cycle of therapy was 805/microliters and the median platelet nadir was 48,000/microliters.",Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7680282/),,"48,000",236273,DB00290,Bleomycin
,7680282,clearance,IdUrd clearance varied from 0.253 liters/min/m2 to 0.503 liters/min/m2 and did not correlate with IdUrd dose.,Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7680282/),[l] / [m2·min],0.253,236274,DB00290,Bleomycin
,7680282,clearance,IdUrd clearance varied from 0.253 liters/min/m2 to 0.503 liters/min/m2 and did not correlate with IdUrd dose.,Phase I clinical and pharmacological study of iododeoxyuridine and bleomycin in patients with advanced cancer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7680282/),[l] / [m2·min],0.503,236275,DB00290,Bleomycin
,7142009,alpha phase half-life,"Biological half-life of NTM in man after a 20 mg bolus injection produced an alpha phase half-life of 3.63 minutes, a beta phase half-life of 84.5 minutes and a volume of distribution at a steady state of 50.3 liters/body.",Pharmacokinetics of neothramycin in animals and man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7142009/),min,3.63,237868,DB00290,Bleomycin
,7142009,beta phase half-life,"Biological half-life of NTM in man after a 20 mg bolus injection produced an alpha phase half-life of 3.63 minutes, a beta phase half-life of 84.5 minutes and a volume of distribution at a steady state of 50.3 liters/body.",Pharmacokinetics of neothramycin in animals and man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7142009/),min,84.5,237869,DB00290,Bleomycin
,7142009,volume of distribution at a steady state,"Biological half-life of NTM in man after a 20 mg bolus injection produced an alpha phase half-life of 3.63 minutes, a beta phase half-life of 84.5 minutes and a volume of distribution at a steady state of 50.3 liters/body.",Pharmacokinetics of neothramycin in animals and man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7142009/),[l] / [body],50.3,237870,DB00290,Bleomycin
,2429861,apparent half-time of absorption,The apparent half-time of absorption for the alpha-phase was 1.1 and 17.9 hr for the beta-phase.,"Pharmacokinetics, subcellular distribution, and covalent binding of [3H]bleomycin in hamsters after intratracheal administration. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429861/),h,1.1,240136,DB00290,Bleomycin
,2429861,apparent half-time of absorption,The apparent half-time of absorption for the alpha-phase was 1.1 and 17.9 hr for the beta-phase.,"Pharmacokinetics, subcellular distribution, and covalent binding of [3H]bleomycin in hamsters after intratracheal administration. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429861/),h,17.9,240137,DB00290,Bleomycin
,2429861,apparent half-life removal,The plasma disappearance curve of [3H]BLM fits to a two-compartmental model with the apparent half-life removal for the alpha-phase being 1.6 hr and for the beta-phase 116.9 hr.,"Pharmacokinetics, subcellular distribution, and covalent binding of [3H]bleomycin in hamsters after intratracheal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429861/),h,1.6,240138,DB00290,Bleomycin
,2429861,apparent half-life removal,The plasma disappearance curve of [3H]BLM fits to a two-compartmental model with the apparent half-life removal for the alpha-phase being 1.6 hr and for the beta-phase 116.9 hr.,"Pharmacokinetics, subcellular distribution, and covalent binding of [3H]bleomycin in hamsters after intratracheal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429861/),h,116.9,240139,DB00290,Bleomycin
,2429861,half-lives,"Of the eight tissues, the spleen had the shortest (2.0 hr) and kidney the longest (12.1 hr), and the remaining tissues had half-lives which ranged from 4 to 10 hr.","Pharmacokinetics, subcellular distribution, and covalent binding of [3H]bleomycin in hamsters after intratracheal administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2429861/),h,4 to 10,240140,DB00290,Bleomycin
,1714790,volume of distribution at steady-state,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [kg],0.398,242987,DB00290,Bleomycin
,1714790,systemic clearance,"For this patient, both the volume of distribution at steady-state (0.398 l/kg) and systemic clearance (0.0956 l/h/kg) of methotrexate were increased compared with values observed in adult patients with osteosarcoma.",Disposition of high-dose methotrexate in an obese cancer patient. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),[l] / [h·kg],0.0956,242988,DB00290,Bleomycin
,1714790,terminal elimination half-life,"The terminal elimination half-life (9.29 hours) of methotrexate was similar to other reported values in adult patients, thus indicating that increases in methotrexate volume of distribution and clearance may offset each other in obesity.",Disposition of high-dose methotrexate in an obese cancer patient. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1714790/),h,9.29,242989,DB00290,Bleomycin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.71,244792,DB00290,Bleomycin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],4.32,244793,DB00290,Bleomycin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],7.95,244794,DB00290,Bleomycin
,28375127,Maximum plasma concentration (Cmax),"Maximum plasma concentration (Cmax) of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) were 7.71, 4.32, 7.95 and 6.51µg/ml respectively.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [ml],6.51,244795,DB00290,Bleomycin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],118.30,244796,DB00290,Bleomycin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],82.11,244797,DB00290,Bleomycin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],245.54,244798,DB00290,Bleomycin
,28375127,Area under the curve,"Area under the curve values of ABVD were 118.30, 82.11, 245.54 and 86.62µg/ml*h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[μg] / [h·ml],86.62,244799,DB00290,Bleomycin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],346.69,244800,DB00290,Bleomycin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],2499.44,244801,DB00290,Bleomycin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],45.90,244802,DB00290,Bleomycin
,28375127,Clearances,"Clearances of ABVD were 346.69, 2499.44, 45.90 and 5800.05ml/h.",Pharmacokinetic evaluation of anticancer drugs in Hodgkin's lymphoma patients after their simultaneous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28375127/),[ml] / [h],5800.05,244803,DB00290,Bleomycin
,1725271,t1/2,"The free substance is cleared relatively quickly from the organism both after intravenous and intraperitoneal administration (t1/2 0.17 and 2.41 h, respectively), and is excreted predominantly via the urinary tract.",Pharmacokinetic behavior of [57Co]bleomycin liposomes in mice: comparison with the unencapsulated substance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725271/),h,0.17,245588,DB00290,Bleomycin
,1725271,t1/2,"The free substance is cleared relatively quickly from the organism both after intravenous and intraperitoneal administration (t1/2 0.17 and 2.41 h, respectively), and is excreted predominantly via the urinary tract.",Pharmacokinetic behavior of [57Co]bleomycin liposomes in mice: comparison with the unencapsulated substance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1725271/),h,2.41,245589,DB00290,Bleomycin
,1688516,major response rate (CR + MR),The major response rate (CR + MR) was thus 35%.,A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1688516/),%,35,250050,DB00290,Bleomycin
,26992379,half-time,"Pharmacokinetic analysis of the data revealed a monophasic serum clearance curve, which demonstrates slow elimination of bleomycin, being less than 500 ml/min and a half-time of 30 min.",Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26992379/),min,30,254868,DB00290,Bleomycin
,2410121,Steady-state concentrations,Steady-state concentrations ranged from 4 to 15 micrograms/L and showed important variations among patients.,Clinical pharmacokinetics of vindesine infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2410121/),[μg] / [l],4 to 15,255313,DB00290,Bleomycin
,6177409,limit of detection,The assay was reproducible with a limit of detection in plasma of 200 ng/liter.,Development and application of a radioimmunoassay for pepleomycin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6177409/),[ng] / [l],200,260968,DB00290,Bleomycin
,6177409,elimination half-life,The drug disappeared from the plasma with an elimination half-life of approximately 3 hours.,Development and application of a radioimmunoassay for pepleomycin. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6177409/),h,3,260969,DB00290,Bleomycin
,30951312,IC50,"Through a phenotypic high-throughput screen using a serum response element luciferase promoter, we identified a novel 5-aryl-1,3,4-oxadiazol-2-ylthiopropionic acid lead inhibitor of Rho/myocardin-related transcription factor (MRTF)/serum response factor (SRF)-mediated gene transcription with good potency (IC50 = 180 nM).","5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30951312/),nM,180,262731,DB00290,Bleomycin
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,43,263580,DB00290,Bleomycin
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,59,263581,DB00290,Bleomycin
,9074848,overall response rates,Liposomal doxorubicin monotherapy in patients with AIDS-related Kaposi's sarcoma produced overall response rates (complete plus partial) of 43 and 59% in large comparative studies and 67 to 100% in noncomparative studies which included > or = 20 patients.,"Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,67,263582,DB00290,Bleomycin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,43,263583,DB00290,Bleomycin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,25,263584,DB00290,Bleomycin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,59,263585,DB00290,Bleomycin
,9074848,overall response rates,"In comparative studies, liposomal doxorubicin was significantly more effective than the combination of standard doxorubicin, bleomycin and vincristine (overall response rates of 43 and 25%, respectively) and bleomycin and vincristine (BV) [overall response rates of 59 and 23%, respectively].","Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9074848/),%,23,263586,DB00290,Bleomycin
